|
45 |
자궁체부암 |
A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC).
|
2025-09-26 |
23 |
|
44 |
자궁체부암 |
Is presumed clinical stage I endometrial cancer using PET-CT and MRI accurate in predicting surgical staging?
|
2025-09-26 |
13 |
|
43 |
자궁체부암 |
Modifying surgical extents in patients with preoperatively presumed early-stage endometrial cancer based on ProMisE classification: a retrospective, single-center study.
|
2025-09-26 |
14 |
|
42 |
난소암 |
Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized Clinical Trial
|
2025-09-26 |
16 |
|
41 |
난소암 |
Efficacy and Safety of Chemotherapy Combined with Hormonal Therapy in Heavily Pretreated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ELSA/KGOG3049): A Multicenter Pilot Study
|
2025-09-26 |
17 |
|
40 |
난소암 |
Radiotherapy quality assurance program of ongoing clinical trial using stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC): a dummy run study of a prospective, randomized, multicenter phase III trial (KGOG 3064/KROG 2204)
|
2025-09-26 |
11 |
|
39 |
난소암 |
A randomized, multicenter, open-label phase III trial of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in platinum-resistant recurrent ovarian cancer: a rationale and study design of the KOV-HIPEC-02 trial
|
2025-09-26 |
16 |
|
38 |
난소암 |
Efficacy of Chemotherapy Following Prior PARP-Inhibitor Treatment in Patients with Ovarian Cancer
|
2025-09-26 |
17 |
|
37 |
자궁경부암 |
Novel biomarker discovery-coupled plasma therapy with enhanced tumor penetration for non-surgical treatment of cervical cancer
|
2025-09-26 |
24 |
|
36 |
자궁경부암 |
Increased cardiovascular disease risk among adolescent and young adult survivors of cervical cancer
|
2025-09-26 |
9 |
